Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ICAD - Icad Inc


IEX Last Trade
1.61
0.050   3.106%

Share volume: 63,275
Last Updated: Fri 30 Aug 2024 09:59:51 PM CEST
Data Processing, Hosting, and Related Services: -0.44%

PREVIOUS CLOSE
CHG
CHG%

$1.56
0.05
3.21%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
5%
Profitability 0%
Dept financing 21%
Liquidity 31%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-5.29%
1 Month
18.38%
3 Months
6.98%
6 Months
-8.52%
1 Year
-29.07%
2 Year
-41.67%
Key data
Stock price
$1.61
P/E Ratio 
-18.74
DAY RANGE
N/A - N/A
EPS 
-$0.09
52 WEEK RANGE
$1.18 - $2.65
52 WEEK CHANGE
-$0.32
MARKET CAP 
42.729 M
YIELD 
N/A
SHARES OUTSTANDING 
26.540 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
1.15
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$95,374
AVERAGE 30 VOLUME 
$219,416
Company detail
CEO:
Region: US
Website: icadmed.com
Employees: 447
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Data Processing, Hosting, and Related Services
Sector: Information

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.

Recent news